Houston Technology Center Client Company Salient Pharmaceuticals Incorporated Receives $2 Million Commercialization Award From The Texas Emerging Technology Fund  
1/29/2010 11:16:52 AM

HOUSTON, Jan. 29 /PRNewswire/ -- Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.